Skip to main content
Top
Published in: Molecular Cancer 1/2024

Open Access 01-12-2024 | Correction

Correction: Hsa_circ_001680 affects the proliferation and migration of CRC and mediates its chemoresistance by regulating BMI1 through miR-340

Authors: Xiangyu Jian, Han He, Jiehong Zhu, Qi Zhang, Zhongxin Zheng, Xiangjing Liang, Liuyan Chen, Meiling Yang, Kaiyue Peng, Zhaowen Zhang, Tengfei Liu, Yaping Ye, Hongli Jiao, Shuyang Wang, Weijie Zhou, Yanqing Ding, Tingting Li

Published in: Molecular Cancer | Issue 1/2024

Login to get access

Excerpt

Correction: Mol Cancer 19, 20 (2020)
Metadata
Title
Correction: Hsa_circ_001680 affects the proliferation and migration of CRC and mediates its chemoresistance by regulating BMI1 through miR-340
Authors
Xiangyu Jian
Han He
Jiehong Zhu
Qi Zhang
Zhongxin Zheng
Xiangjing Liang
Liuyan Chen
Meiling Yang
Kaiyue Peng
Zhaowen Zhang
Tengfei Liu
Yaping Ye
Hongli Jiao
Shuyang Wang
Weijie Zhou
Yanqing Ding
Tingting Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2024
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-024-02018-7

Other articles of this Issue 1/2024

Molecular Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine